It could simply be that dr Bruce was talking too openly about his findings and leronlimab effects while a blinded trial is in process. The tight connection between incell and cytodyn might be a problem as well, the lab needs to be impartial and us influenced buy the company that is doing the trial. I am sure dr Bruce and Nader discussed this and know the risk of the fda not liking this. They might be just playing it safe.